We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
+88.01%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$492M
AUM Growth
+$193M
Cap. Flow
-$12.2M
Cap. Flow %
-2.48%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$10.7M

Top Sells

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$22.6M
2
UBX
Unity Biotechnology
UBX
+$386K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPP
1
Rapport Therapeutics
RAPP
$2.05B
$111M 22.49%
3,728,738
– –
BEAM icon
2
Beam Therapeutics
BEAM
$2.73B
$110M 22.38%
4,540,132
– –
MAZE
3
Maze Therapeutics
MAZE
$1.53B
$107M 21.7%
4,120,053
– –
VIR icon
4
Vir Biotechnology
VIR
$1.5B
$73.8M 14.98%
12,916,663
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$336M
$44.8M 9.1%
2,759,072
+938,438
+52% +$10.7M
ERAS icon
6
Erasca
ERAS
$6.48B
$24.1M 4.9%
11,055,554
– –
GOSS icon
7
Gossamer Bio
GOSS
$87.2M
$21.2M 4.3%
8,055,916
– –
QTTB icon
8
Q32 Bio
QTTB
$462M
$635K 0.13%
320,482
– –
CERO
9
DELISTED
CERo Therapeutics
CERO
$114K 0.02%
22,389
– –
UBX
10
DELISTED
Unity Biotechnology
UBX
– –
-1,004,817
Closed -$386K
VERV
11
DELISTED
Verve Therapeutics
VERV
– –
-2,008,809
Closed -$22.6M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q3 2025 Portfolio in Review

As of Q3 2025, Arch Venture Management held 11 positions worth $492M, up 65% from $299M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management's Q3 2025 filing shows 1 increased and 2 closed positions. The largest sale was Verve Therapeutics, an estimated $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Arch Venture Management added most to Lyell Immunopharma in Q3 2025, an estimated $10.7M increase.
  • Arch Venture Management fully exited Verve Therapeutics in Q3 2025, selling an estimated $22.6M.
  • Arch Venture Management's ten largest holdings make up 100% of its $492M portfolio in Q3 2025.
  • Arch Venture Management opened 0 new positions and closed 2 in Q3 2025.
  • Arch Venture Management's portfolio value rose 65% quarter-over-quarter to $492M.

Based on Arch Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.